# Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

> **NCT00578175** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1851 (actual)

## Conditions studied

- Varicella
- Rubella
- Mumps
- Measles

## Interventions

- **BIOLOGICAL:** Priorix-Tetra™ (MMRV vaccine 208136)
- **BIOLOGICAL:** ProQuad®
- **BIOLOGICAL:** Havrix®
- **BIOLOGICAL:** Prevnar®

## Key facts

- **NCT ID:** NCT00578175
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-20
- **Primary completion:** 2009-02-24
- **Final completion:** 2009-03-17
- **Target enrollment:** 1851 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578175, "Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00578175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*